Daniel Hovdal

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Boosting peptide half-life: enabling efficient generation of Fc-peptide conjugates.

Boosting peptide half-life: enabling efficient generation of Fc-peptide conjugates.

Journal: Chemical science

Published: March 31, 2026

Discovery of AZD4144, a Selective and Potent NLRP3 Inhibitor for the Treatment of Inflammatory Diseases.

Discovery of AZD4144, a Selective and Potent NLRP3 Inhibitor for the Treatment of Inflammatory Diseases.

Journal: Journal of medicinal chemistry

Published: July 09, 2025

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.

Journal: Cardiovascular research

Published: August 17, 2024

Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction.

Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction.

Journal: European heart journal

Published: August 01, 2023

Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".

Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction".

Journal: Journal of medicinal chemistry

Published: October 03, 2022

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.

Journal: Journal of medicinal chemistry

Published: August 25, 2022

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice.

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice.

Journal: Molecular therapy. Nucleic acids

Published: October 27, 2021

Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors.

Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors.

Journal: Nature cell biology

Published: August 12, 2021

Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein.

Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein.

Journal: Molecular therapy. Nucleic acids

Published: July 11, 2020

Structural analysis identifies an escape route from the adverse lipogenic effects of liver X receptor ligands.

Structural analysis identifies an escape route from the adverse lipogenic effects of liver X receptor ligands.

Journal: Communications biology

Published: July 19, 2019

Overexpressing cell systems are a competitive option to primary adipocytes when predicting in vivo potency of dual GPR81/GPR109A agonists.

Overexpressing cell systems are a competitive option to primary adipocytes when predicting in vivo potency of dual GPR81/GPR109A agonists.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: June 02, 2017

Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.

Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.

Journal: PloS one

Published: September 09, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026